Lung cancer
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients aged >=18 years, no gendeer limit. 2. For patients with histologically or cytologically proven non-small cell lung cancer, there is no limit to tumor stage. 3. Predicted survival >=3 months. 4. Lung cancer specimens were obtained by surgery or needle biopsy during hospitalization, and peripheral blood samples were collected during hospitalization, and NGS detection of tumor tissue and single cell sequencing detection of peripheral blood CTC were performed. The sequencing results were well preserved and accessible. To improve the reference protocol for their subsequent treatment. The following conditions shall be met for sampling and storage: (1) Surgical sampling: each cancer tissue sample of about 50mg was placed in pre-cold sterile PBS buffer immediately after surgery and tested within 48 hours; (2) Puncture sampling: Puncture samples were soaked in formalin and tested within 48 hours after sampling; (3) Peripheral blood sample: 7.5mL of peripheral blood was collected from the medical anticoagulant collection vessel. The anticoagulant was EDTA K2. Store at 4?, avoid freezing during storage, handling and transportation, and test within 72 hours.
Exclusion criteria
Exclusion criteria: 1. Patients who have previously received radiotherapy and chemotherapy. 2. Patients who had previously received targeted therapy or PD-1/PD-L1 immunotherapy. 3. Patients who had previously received CAR-T cell therapy. 4. Had received systemic corticosteroids (more than 10mg of prednisone equivalent daily) or other immunosuppressive agents for more than 7 days in the 2 weeks prior to sampling (in the absence of active autoimmune disease). 5. Patients with 2 or more previous or current primary tumors.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| CTC single cell whole gene sequencing; | — |
Countries
China
Contacts
Army Specialty Medical Center